Q1 2026 Arvinas Inc Earnings Call Transcript
Key Points
- FDA approval of VEPPANU for ESR1-mutant, ER-positive, HER2-negative advanced breast cancer, marking the first-ever approval of a heterobifunctional PROTAC degrader.
- Arvinas Inc (ARVN) entered a global licensing agreement with Rigel Pharmaceuticals for the commercialization, development, and manufacturing of VEPPANU, ensuring its availability to patients.
- Strong preclinical and Phase 1 data for ARV-102, showing significant reductions in LRRK2 and associated biomarkers, supporting its advancement into PSP trials.
- Arvinas Inc (ARVN) maintains a healthy balance sheet with $614.9 million in cash equivalents, allowing continued investment in their pipeline through 2028.
- Successful cost reduction initiatives have significantly decreased expenses, with non-GAAP R&D and G&A expenses down by 32% and 44%, respectively, compared to the previous year.
- Revenue for Q1 2026 decreased significantly to $15.6 million from $188.8 million in the same period of 2025, primarily due to changes in the Vega Strant collaborative agreement with Pfizer.
- The Phase 1b clinical trial for ARV-102 in PSP is on hold in the U.S. pending additional data, delaying its initiation until the end of 2026.
- Ongoing trials for VEPPANU are being run by Arvinas Inc (ARVN) and Pfizer, with future development costs falling to Rigel, creating uncertainty in future trial management.
- The competitive landscape for KRAS inhibitors/degraders is rapidly evolving, posing challenges for Arvinas Inc (ARVN) to differentiate its ARV-806 program.
- The company faces potential challenges in translating preclinical success of ARV-027 in SBMA mouse models to clinical benefit in humans.
Good day, and thank you for standing by. Welcome to the Arvinas first-quarter 2026 earnings call. (Operator Instructions) Please be advised that today's conference is being recorded.
I would like to hand the conference over to your first speaker today, Jeff Boyle, Head of Investor Relations. Please go ahead.
Good morning, everyone. Thank you for joining us.
Earlier today, we issued a press release with our first-quarter 2026 financial results, which is available in the Investor and Media section of our website at arvinas.com. Joining us on the call today, we have Randy Teel, our President and CEO; Noah Berkowitz, our Chief Medical Officer; Angela Cacace, our Chief Scientific Officer; and Andrew Saik, our Chief Financial Officer.
Before we begin, I'll remind you that today's discussion contains forward-looking statements that involve risks, uncertainties, and assumptions. These risks and uncertainties are outlined in today's press release and in the company's recent filings
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
